Heart fat melted by diabetes drugs? new MRI study investigates

NCT ID NCT03498001

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether GLP-1 agonists, a class of diabetes drugs, can reduce fat buildup in the heart muscle of people with type 2 diabetes. Researchers used MRI scans to measure heart fat before and after 6 months of treatment in 42 adults over 50. The goal was to understand how these drugs might protect the heart beyond just lowering blood sugar.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLP-1 agonists (liraglutide, semaglutide, dulaglutide)
What this could lead to: If successful, this could show that GLP-1 drugs reduce fat in the heart, pointing to a new way to protect against heart failure in diabetes.
What could go wrong: This is a small, completed study with only 42 participants and no control group. Results may not apply to everyone, and the heart fat changes may not lead to clear health benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE II DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE II DIABETES

Contacts and locations

Locations

Chu Dijon Bourgogne

Dijon, 21000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.